Abstract
Background: Epigenetic changes are considered to be a frequent event during tumor development. Various methylation changes have been identified and show promise as potential cancer biomarkers. The aim of this study was to investigate promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium.
Methods: To search for promoter methylation of GATA4 and TP53 genes we used methylation-specific PCR (MSP) to compare the methylation status of 54 patients with endometrioid carcinoma of endometrium and 18 patients with normal endometrial tissue.
Results: In our study MSP revealed GATA4 promoter methylation in 44 of 54 in the carcinoma group (81.5%), and in none of the control group. No methylation was observed in TP53 gene.
Conclusions: In conclusion, our study showed that there is significantly higher methylation in GATA4 gene in the endometrial cancer group compared with samples of non-neoplastic endometrium. The finding suggests the importance of hypermethylation of this gene in endometrial carcinogenesis and could have implications for future diagnostic and therapeutic strategies for endometrial cancer based on epigenetic changes.
Acknowledgments
The authors are grateful to Ian McColl MD, PhD for assistance with the manuscript.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: This study was supported by the project MH CZ-DRO (UHHK, 00179906) and by project PRVOUK of the Charles University in Prague, Czech Republic.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Available from: http://globocan.iarc.fr. Accessed 16 October, 2013.Search in Google Scholar
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10–7.10.1016/0090-8258(83)90111-7Search in Google Scholar
3. Banno K, Kisu I, Yanokura M, Masuda K, Kobayashi Y, Ueki A, et al. Endometrial cancer and hypermethylation: regulation of DNA and microRNA by epigenetics. Biochem Res Int 2012;2012:738274.10.1155/2012/738274Search in Google Scholar PubMed PubMed Central
4. Plataniotis G, Castiglione M. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;5:41–5.10.1093/annonc/mdq245Search in Google Scholar PubMed
5. Tao MH, Freudenheim JL. DNA methylation in endometrial cancer. Epigenetics 2010;5:491–8.10.4161/epi.5.6.12431Search in Google Scholar PubMed PubMed Central
6. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer 2010;1:1178–88.10.1177/1947601911404223Search in Google Scholar PubMed PubMed Central
7. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000;275:38949–52.10.1074/jbc.R000029200Search in Google Scholar PubMed
8. Tremblay JJ, Viger RS. Transcription factor GATA-4 enhances Mullerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-1. Mol Endocrinol 1999;13:1388–401.Search in Google Scholar
9. Viger RS, Mertineit C, Trasler JM, Nemer M. Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the Mullerian inhibiting substance promoter. Development 1998;125:2665–75.10.1242/dev.125.14.2665Search in Google Scholar PubMed
10. Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK. Endogenous expression of Mullerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci USA 2000;97:1624–9.10.1073/pnas.97.4.1624Search in Google Scholar PubMed PubMed Central
11. Silverman E, Eimerl S, Orly J. CCAAT enhancer-binding protein beta and GATA-4 binding regions within the promoter of the steroidogenic acute regulatory protein (StAR) gene are required for transcription in rat ovarian cells. J Biol Chem 1999;274:17987–96.10.1074/jbc.274.25.17987Search in Google Scholar PubMed
12. Lane DP. p53 and human cancers. Br Med Bull 1994;50:582–99.10.1093/oxfordjournals.bmb.a072911Search in Google Scholar PubMed
13. Oren M, Rotter V. Introduction: p53 – the first twenty years. Cell Mol Life Sci 1999;55:9–11.10.1007/s000180050265Search in Google Scholar PubMed
14. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15–6.10.1038/358015a0Search in Google Scholar PubMed
15. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632–42.10.1200/JCO.2004.07.151Search in Google Scholar PubMed
16. Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059–70.10.1182/blood.V93.12.4059Search in Google Scholar
17. Prokhortchouk E, Hendrich B. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 2002;21:5394–9.10.1038/sj.onc.1205631Search in Google Scholar PubMed
18. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295–304.10.1038/nrg2540Search in Google Scholar PubMed
19. Nieminen TT, Gylling A, Abdel-Rahman WM, Nuorva K, Aarnio M, Renkonen-Sinisalo L, et al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 2009;15:5772–83.10.1158/1078-0432.CCR-09-0506Search in Google Scholar PubMed
20. Tavassoéli FA, Devilee P, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press – WHO, 2003.Search in Google Scholar
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821–6.10.1073/pnas.93.18.9821Search in Google Scholar PubMed PubMed Central
22. Amatya VJ, Naumann U, Weller M, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol 2005;110: 178–84.10.1007/s00401-005-1041-5Search in Google Scholar PubMed
23. Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129–39.10.1016/j.ygyno.2007.12.017Search in Google Scholar PubMed
24. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 2003;23:8429–39.10.1128/MCB.23.23.8429-8439.2003Search in Google Scholar PubMed PubMed Central
25. Wen XZ, Akiyama Y, Pan KF, Liu ZJ, Lu ZM, Zhou J, et al. Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas. World J Gastroenterol 2010;16: 1201–8.10.3748/wjg.v16.i10.1201Search in Google Scholar PubMed PubMed Central
26. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, et al. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 2004;10:7917–24.10.1158/1078-0432.CCR-04-1140Search in Google Scholar PubMed
27. Guo M, House MG, Akiyama Y, Qi Y, Capagna D, Harmon J, et al. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer 2006;119:2078–83.10.1002/ijc.22092Search in Google Scholar PubMed
28. Vaitkiene P, Skiriute D, Skauminas K, Tamasauskas A. GATA4 and DcR1 methylation in glioblastomas. Diagn Pathol 2013;8:7.10.1186/1746-1596-8-7Search in Google Scholar PubMed PubMed Central
29. Wakana K, Akiyama Y, Aso T, Yuasa Y. Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett 2006;241:281–8.10.1016/j.canlet.2005.10.039Search in Google Scholar PubMed
30. Chmelarova M, Dvorakova E, Spacek J, Laco J, Palicka V. Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157:294–7.10.5507/bp.2013.079Search in Google Scholar PubMed
31. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64: 6476–81.10.1158/0008-5472.CAN-04-1529Search in Google Scholar PubMed
32. Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012;50:1707–21.Search in Google Scholar
33. Szymanska K, Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 2003;50:231–8.10.18388/abp.2003_3731Search in Google Scholar
34. Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M, et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010;2010:984013.10.1155/2010/984013Search in Google Scholar PubMed PubMed Central
35. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369–79.10.1002/cncr.10498Search in Google Scholar PubMed
36. Kaku T, Kamura T, Hirakawa T, Sakai K, Amada S, Kobayashi H, et al. Endometrial carcinoma associated with hyperplasia – immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 1999;72:51–5.10.1006/gyno.1998.5230Search in Google Scholar PubMed
37. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177–85.Search in Google Scholar
38. Almeida LO, Custodio AC, Pinto GR, Santos MJ, Almeida JR, Clara CA, et al. Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. Genet Mol Res 2009;8:8–18.10.4238/vol8-1gmr518Search in Google Scholar PubMed
39. Agirre X, Novo FJ, Calasanz MJ, Larrayoz MJ, Lahortiga I, Valganon M, et al. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 2003;38:201–8.10.1002/mc.10159Search in Google Scholar PubMed
40. Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M, Palicka V. Methylation in the p53 promoter in epithelial ovarian cancer. Clin Transl Oncol 2013;15:160–3.10.1007/s12094-012-0894-zSearch in Google Scholar PubMed
41. Livide G, Epistolato MC, Amenduni M, Disciglio V, Marozza A, Mencarelli MA, et al. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol Oncol Res 2012;18:703–12.10.1007/s12253-012-9498-8Search in Google Scholar PubMed
42. Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, et al. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Hum Mol Genet 2010;19:2936–46.10.1093/hmg/ddq199Search in Google Scholar PubMed
43. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpcao PP, Bello MJ, et al. Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res 2008;41:539–43.10.1590/S0100-879X2008000600017Search in Google Scholar PubMed
44. Sidhu S, Martin E, Gicquel C, Melki J, Clark SJ, Campbell P, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 2005;31:549–54.10.1016/j.ejso.2005.01.013Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin/Boston
